Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Bought by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL raised its position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 37.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 58,418 shares of the biopharmaceutical company’s stock after purchasing an additional 15,932 shares during the period. Gamco Investors INC. ET AL owned 0.06% of Revance Therapeutics worth $178,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Alliancebernstein L.P. increased its holdings in Revance Therapeutics by 7.3% in the fourth quarter. Alliancebernstein L.P. now owns 3,497,112 shares of the biopharmaceutical company’s stock valued at $10,631,000 after buying an additional 236,641 shares during the last quarter. Magnetar Financial LLC boosted its position in shares of Revance Therapeutics by 2.2% during the 4th quarter. Magnetar Financial LLC now owns 2,556,345 shares of the biopharmaceutical company’s stock worth $7,771,000 after acquiring an additional 56,174 shares in the last quarter. State Street Corp increased its holdings in shares of Revance Therapeutics by 6.6% in the 3rd quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock valued at $12,632,000 after acquiring an additional 150,323 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Revance Therapeutics by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 2,297,582 shares of the biopharmaceutical company’s stock worth $6,986,000 after acquiring an additional 7,928 shares in the last quarter. Finally, Gabelli Funds LLC lifted its stake in Revance Therapeutics by 15.7% during the fourth quarter. Gabelli Funds LLC now owns 1,262,487 shares of the biopharmaceutical company’s stock worth $3,838,000 after purchasing an additional 171,323 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC opened at $3.65 on Friday. Revance Therapeutics, Inc. has a one year low of $2.30 and a one year high of $6.65. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The company has a 50-day simple moving average of $3.65 and a 200-day simple moving average of $3.91.

Wall Street Analysts Forecast Growth

RVNC has been the topic of a number of research analyst reports. Barclays cut their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. StockNews.com started coverage on shares of Revance Therapeutics in a research note on Saturday. They set a “hold” rating on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Revance Therapeutics has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.